Ardent Health (NYSE:ARDT) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Ardent Health (NYSE:ARDT) posted its quarterly earnings results on Tuesday. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.18 by $0.10, Zacks reports. Ardent Health had a return on equity of 14.30% and a net margin of 2.15%. Ardent Health updated its FY 2026 guidance to 0.900-1.270 EPS.

Ardent Health Trading Up 1.5%

ARDT traded up $0.15 on Tuesday, hitting $10.13. The company had a trading volume of 492,301 shares, compared to its average volume of 393,411. The firm has a market cap of $1.45 billion, a P/E ratio of 10.55 and a beta of 0.93. Ardent Health has a 1 year low of $8.07 and a 1 year high of $15.48. The company’s fifty day moving average price is $9.25 and its 200 day moving average price is $9.85. The company has a current ratio of 1.97, a quick ratio of 1.85 and a debt-to-equity ratio of 0.64.

Hedge Funds Weigh In On Ardent Health

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its position in Ardent Health by 1,177.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock valued at $25,000 after acquiring an additional 2,638 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Ardent Health in the 3rd quarter valued at about $61,000. New York State Common Retirement Fund grew its position in Ardent Health by 121.4% in the 2nd quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock valued at $85,000 after acquiring an additional 3,400 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Ardent Health in the 3rd quarter valued at about $145,000. Finally, Fox Run Management L.L.C. acquired a new position in Ardent Health in the 4th quarter valued at about $147,000.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Ardent Health from $12.00 to $11.00 and set a “neutral” rating on the stock in a report on Tuesday, January 20th. Zacks Research upgraded shares of Ardent Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, March 25th. Leerink Partners reduced their price objective on shares of Ardent Health from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Finally, Royal Bank Of Canada reduced their price objective on shares of Ardent Health from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Monday, March 9th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Ardent Health currently has a consensus rating of “Hold” and a consensus price target of $14.25.

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.